Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tolerx, Inc.

http://www.tolerx.com

Latest From Tolerx, Inc.

Asia Deal Watch: Astellas Acquires Global Rights To KaliVir Oncolytic Virus Candidate

Plus deals involving SELLAS/3D Medicines, Kyowa Kirin/InveniAI, JW/Voronoi, Y-mAbs/Takeda, Horizon Discovery/Sanyou, Sentinel Oncology/PharmaEngine

Deals Business Strategies

Westlake Village BioPartners Closes Two VC Funds Totaling $500m

A $70m fund will back prior investments, while a $430m fund will launch new biotech firms. Harper and Seidenberg tapped into their Amgen connections for the CEO who helms new company Acelyrin.

Financing Innovation

Market Brief: Tissue-Engineered Wound Care Market Expected To Reach $1.9Bn By 2024 Amid Rising Chronic Disease

The skin replacement market is led by three key players who have all been impacted by COVID-19, but the sector may see a quicker rebound than others as treatments cannot be deferred for a long time.

Wound Management Wound Healing & Tissue Repair

ADDF’s Fillit On FDA’s Tough Aducanumab Decision, Advances In Alzheimer’s

The pending US FDA decision on Biogen’s drug overshadows progress in Alzheimer’s diagnosis, symptomatic treatments and the need to keep studying anti-tau therapies after Roche’s setback.

Neurology Research and Development Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register